Statement: both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies.
Primary_evidence: INTERVENTION 1:    Physician's Choice   Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine), until progression or unacceptable toxicity develops. INTERVENTION 2:    Niraparib   Niraparib 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops